---
schema_version: "secwatch.filing_event.v1"
accession: "0001663577-25-000033"
form_type: "8-K"
ticker: "SKVI"
cik: "0001085277"
company_name: "SKINVISIBLE, INC."
filed_at: "2025-01-23T23:59:59+00:00"
generated_at: "2026-05-27T13:17:47.800435+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Skinvisible licensee Quoin reports positive Netherton Syndrome clinical results; $5M milestone payment upon approval

## Summary
- Quoin's QRX003 (using Invisicare) showed 'severe' to 'mild' improvement after 6 weeks in Netherton Syndrome studies.
- FDA cleared a whole-body study at Northwestern University; no adverse events reported to date.
- Clinical trials expanded to UK, Ireland, and Saudi Arabia; product licensed in 60 countries.
- Skinvisible to receive $5M milestone payment plus ongoing royalties upon FDA or EU approval.
- Skinvisible actively seeking partnerships for transdermal obesity therapies and other formulations.

## SEC filing metadata
- accession: 0001663577-25-000033
- form_type: 8-K
- ticker: SKVI
- cik: 0001085277
- company_name: SKINVISIBLE, INC.
- filed_at: 2025-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1085277/000166357725000033/0001663577-25-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1085277/000166357725000033/skvi8k_012325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001663577-25-000033
- JSON: https://secwatch.observer/filing/0001663577-25-000033.json
- Plain text: https://secwatch.observer/filing/0001663577-25-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.